Oncopeptides AB (publ)

Stockholm Stock Exchange ONCO.ST

Oncopeptides AB (publ) Capital Expenditure for the year ending December 31, 2023: USD -11.45 K

Oncopeptides AB (publ) Capital Expenditure is USD -11.45 K for the year ending December 31, 2023, a 95.22% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Oncopeptides AB (publ) Capital Expenditure for the year ending December 31, 2022 was USD -239.42 K, a -541.46% change year over year.
Oncopeptides AB (publ) Capital Expenditure for the year ending December 31, 2021 was USD -37.32 K, a 98.21% change year over year.
Oncopeptides AB (publ) Capital Expenditure for the year ending December 31, 2020 was USD -2.08 M, a -644.66% change year over year.
Oncopeptides AB (publ) Capital Expenditure for the year ending December 31, 2019 was USD -279.62 K, a -573.58% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Stockholm Stock Exchange: ONCO.ST

Oncopeptides AB (publ)

CEO	Ms. Sofia Heigis M.Sc.
IPO Date	Feb. 22, 2017
Location	Sweden
Headquarters	Vastra Tradgardsgatan 15
Employees	79
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years